Literature DB >> 17979586

Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.

Wolfgang Aichhorn1, Josef Marksteiner, Thomas Walch, Gerald Zernig, Hartmann Hinterhuber, Christoph Stuppaeck, Georg Kemmler.   

Abstract

BACKGROUND: Risperidone and olanzapine are second-generation antipsychotics that are increasingly used in child and adolescent psychiatry. So far, little is known about plasma concentrations and concentration-to-dose (C/D) ratios of these agents in children and adolescents compared to adults.
METHOD: This study investigated whether age and gender influence risperidone and olanzapine plasma concentration by determining risperidone and olanzapine plasma levels by tandem mass spectrometry in 162 Caucasian patients (98 risperidone and 64 olanzapine).
RESULTS: For risperidone and 9-hydroxyrisperidone, the C(total)/D ratio was almost identical in both age groups (10-18 and 19-45 years, respectively). In the younger age group, females exhibited significantly higher total plasma levels than males while receiving similar doses of risperidone. For olanzapine, in adolescents significantly higher C/D ratios were detected by an average of 43% (after adjustment for weight: 34%) compared to adults.
CONCLUSION: This study demonstrates an age effect for olanzapine but not for risperidone resulting in higher olanzapine plasma levels in younger patients. For risperidone, we found a gender effect as female adolescent patients had significantly higher risperidone plasma concentrations than male adolescent patients. Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979586     DOI: 10.1089/cap.2006.0045

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  14 in total

1.  Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents.

Authors:  Yeni Kim; Soo-Churl Cho; Min-Sup Shin; Jae-Won Kim; Sang-Chul Choi; Boong-Nyun Kim
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

2.  Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.

Authors:  Chadi Albert Calarge; Del D Miller
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-12       Impact factor: 2.576

Review 3.  Pharmacological interventions for prevention of weight gain in people with schizophrenia.

Authors:  Sri Mahavir Agarwal; Nicolette Stogios; Zohra A Ahsan; Jonathan T Lockwood; Markus J Duncan; Hiroyoshi Takeuchi; Tony Cohn; Valerie H Taylor; Gary Remington; Guy E J Faulkner; Margaret Hahn
Journal:  Cochrane Database Syst Rev       Date:  2022-10-03

Review 4.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

5.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

Review 6.  Secondary effects of antipsychotics: women at greater risk than men.

Authors:  Mary V Seeman
Journal:  Schizophr Bull       Date:  2008-04-09       Impact factor: 9.306

7.  Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.

Authors:  Catherine M T Sherwin; Shannon N Saldaña; Robert R Bies; Michael G Aman; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2012-10       Impact factor: 3.681

8.  Post-drug consequences of chronic atypical antipsychotic drug administration on the ability to adjust behavior based on feedback in young monkeys.

Authors:  Dorothy J Mandell; Alan Unis; Gene P Sackett
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

9.  Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.

Authors:  R Taurines; S Fekete; A Preuss-Wiedenhoff; A Warnke; C Wewetzer; P Plener; R Burger; M Gerlach; M Romanos; K M Egberts
Journal:  J Neural Transm (Vienna)       Date:  2022-03-18       Impact factor: 3.850

10.  Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil.

Authors:  Izabela Fulone; Marcus Tolentino Silva; Luciane Cruz Lopes
Journal:  BMC Psychiatry       Date:  2021-06-29       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.